Table 1. Summary of the different studies with seminal plasma sample analysis of HIV-1 patients under combination antiretroviral therapy and with an undetectable blood plasma viral load.
| Numbers | HIV-1 RNA detection thresholds (copies/ml) | ||||||||
| Studies | Studied period | Patients | SPS | Delay between bpVL and spVL | bpVL | spVL | Prevalence of detectable spVL | Prevalence of patients with at least one detectable spVL | cART regimen of patients with at least one detectable spVL** |
| Vernazza et al. [6] | N/A | 114 | N/A | synchronized | 400 | 400 | N/A | 1.8% (2/114) | Grp 2: 1/2, Grp 3: 1/2 |
| Bujan et al. [17] | 04/1998 - 01/2001 | N/A | N/A | N/A | 20 | 100 | 7.9% (N/A) | N/A | N/A |
| Marcelin et al. [12] | 01/2002 - 01/2008 | 140* | 232 | synchronized | 40 | N/A | 3% (7/232) | 5% (7/140*) | Grp 1: 14.3% (1/7), Grp 2: 57.1% (4/7), Grp 3: 28.6% (2/7) |
| Sheth et al. [11] | N/A | 25 | 116 | synchronized | 50 | 300 | 16.4% (19/116) | 48% (12/25) | Grp 1: 58.3% (7/12); Grp2: 42.7% (5/12) |
| [11] long-term follow-up | N/A | 13 | 13 | synchronized | 50 | 30 | 31% (4/13) | 31% (4/13) | Grp1: 2/4, Grp 2 : 2/4 |
| Halfon et al. [13] | 10/2001 - 03/2009 | 224 | 263 | 28 days (median) | 40 | 40 | 3.8% (10/263) | 4% (9/224) | Grp 1: 0% (0/10), Grp 2: 50% (5/10), Grp 3: 50% (5/10) |
| Dulioust et al. [10] | 01/2002 - 12/2009 | 455 | N/A | up to 2 months | 50 | 100 | N/A | Overall: 3.7% (17/455), 2002*: 15% (6/38), 2003*: 10% (6/60), 2004*: 6% (4/65), 2005*: 1.5% (1/80), 2006–2009 : 0% (0/212) | N/A |
| Lambert-Niclot et al. [14] | 01/2002 - 06/2011 | 304 | 628 | N/A | 20 or 40 | 100 or 200 | N/A | Overall: 6.6% (20/304), 2002: 0% (0/16), 2003*: 3% (1/35), 2004*: 4% (2/30), 2005*: 3% (1/37), 2006*: 4% (1/25), 2007*: 7% (2/37), 2008*: 5% (3/60), 2009* : 6% (4/65), 2010*: 5.5% (3/55), 2011*: 11% (3/27) | Grp 1: 10% (2/20), Grp 2: 70% (14/20), Grp 3: 20% (4/20) |
| Our study | 01/2006 - 12/2011 | 88 | 306 | up to 6 months | 50 | 200 | Overall: 7.5% (23/306) | Overall: 19.3% (17/88) | Grp 1: 11.8% (2/17), Grp 2: 82.4% (14/17), Grp 3: 5.9% (1/17) |
N/A, not available; cART, combination antiretroviral therapy; SPS, seminal plasma sample; bpVL, blood plasma viral load; spVL, seminal plasma viral load; Grp, group.
* Estimated results based on figures and numbers in published studies.
** Group 1: 1 non-nucleosidic reverse transciptase inhibitor+2 nucleosidic reverse transciptase inhibitor, Group 2: 1 protease inhibitor+2 nucleosidic reverse transciptase inhibitor, Group 3: other combination.